92 related articles for article (PubMed ID: 16406869)
1. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.
Bleumer I; Oosterwijk E; Oosterwijk-Wakka JC; Völler MC; Melchior S; Warnaar SO; Mala C; Beck J; Mulders PF
J Urol; 2006 Jan; 175(1):57-62. PubMed ID: 16406869
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
Bleumer I; Knuth A; Oosterwijk E; Hofmann R; Varga Z; Lamers C; Kruit W; Melchior S; Mala C; Ullrich S; De Mulder P; Mulders PF; Beck J
Br J Cancer; 2004 Mar; 90(5):985-90. PubMed ID: 14997194
[TBL] [Abstract][Full Text] [Related]
3. Re: a clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.
Doehn C
J Urol; 2006 Oct; 176(4 Pt 1):1687. PubMed ID: 16952716
[No Abstract] [Full Text] [Related]
4. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
Varga Z; de Mulder P; Kruit W; Hegele A; Hofmann R; Lamers C; Warnaar S; Mala C; Ullrich S; Mulders P
Folia Biol (Praha); 2003; 49(2):74-7. PubMed ID: 12779016
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders P; Bleumer I; Debruyne F; Oosterwijk E
Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
[No Abstract] [Full Text] [Related]
7. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
[TBL] [Abstract][Full Text] [Related]
11. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.
Siebels M; Rohrmann K; Oberneder R; Stahler M; Haseke N; Beck J; Hofmann R; Kindler M; Kloepfer P; Stief C
World J Urol; 2011 Feb; 29(1):121-6. PubMed ID: 20512580
[TBL] [Abstract][Full Text] [Related]
12. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
14. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
16. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
17. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
Kennett RH
Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
[TBL] [Abstract][Full Text] [Related]
18. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
[TBL] [Abstract][Full Text] [Related]
19. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
20. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
